Nephron
Original Paper
Serum Leptin Concentrations in Patients on HemodialysisNakazono H. · Nagake Y. · Ichikawa H. · Makino H.Department of Medicine III, Okayama University Medical School, Okayama, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: September 04, 1998
Issue release date: September 1998
Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 4
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Abstract
Serum leptin concentrations in normal humans have been reported to correlate with the body mass index (BMI) as well as with the body fat mass. In this study, we measured serum leptin concentrations in 107 patients on hemodialysis, 30 of whom had diabetes mellitus as the cause, and examined the clinical significance. Furthermore, we evaluated the effects of high-flux dialysis membranes on serum leptin levels. Serum leptin concentrations had a linear correlation with BMI as well as with the percentage of body fat in patients on hemodialysis. The serum leptin concentrations showed a positive correlation with the serum concentrations of total cholesterol, low-density lipoprotein cholesterol, and triglyceride, the body weight, the BMI, and the percentage of body fat. The serum leptin levels were not different between the diabetic and the nondiabetic groups. The serum leptin levels in the nondiabetic group were nearly fourfold higher in women than in men. We investigated the differences in the rate of reduction in serum leptin after dialysis with polysulfone membrane dialyzers (PS-N and PS-UW) in comparison with a cellulose membrane dialyzer (AM-SD), and as a result, we found that the polysulfone membrane dialyzers removed serum leptin, while the cellulose membrane dialyzer did not. We conclude that in patients on hemodialysis, the serum leptin concentration is a valuable clinical marker of the body fat content and may also contribute to the evaluation of hyperlipidemia.
Related Articles:
References
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.
- Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV: Leptin: The tale of an obesity gene. Diabetes 1996;45:1455–1462.
- Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546–549.
- Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540–543.
- Considine RV, Considine EL, Williams CJ, Nyce MR, Magosin SA, Bauer TL, Rosato EL, Colberg J, Cara JF: Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 1995;95:2986–2988.
- Maffi M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM: Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155–1161.
- Hosoda K, Masuzaki H, Ogawa Y, Miyawaki T, Hiraoka J, Hanaoka I, Yasuno A, Nomura T, Fujisawa Y, Yoshimasa Y, Nishi S, Yamori Y, Nakao K: Development of radioimmunoassay for human leptin. Biochem Biophys Res Commun 1996;221:234–239.
- Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M: Radioimmunoassay of leptin in human plasma. Clin Chem 1996;42:942–946.
- Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292–295.
- Larsson H, Elmstahl S, Ahren B: Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. Diabetes 1996;45:1580–1584.
- Haffner SM, Stern MP, Mittinen H, Wei M, Gingerich RL: Leptin concentrations in diabetic and nondiabetic Mexican-Americans. Diabetes 1996;45:822–824.
- McGregor GP, Desaga JF, Ehlenz K, Fisher A, Heese F, Hegele A, Lammer C, Peiser C, Lang RE: Radioimmunological measurement of leptin in plasma of obese and diabetic human subjects. Endocrinology 1996;137:1501–1504.
-
Heimbürger O, Lönnqvist F, Danielsson A, Nordenström J, Stenvinkel P: Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997:15:1423–1430.
- Young GA, Woodrow G, Kendall S, Oldroyd B, Turney JH, Brownjohn AM, Smith MA: Increased plasma leptin/fat ratio in patients with chronic renal failure: A cause of malnutrition? Nephrol Dial Transplant 1997;12:2318–2323.
- Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BRC, Kurnik PB, O’Connor J, Sinha M, Caro JF: Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997;51:1980–1985.
- Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago JV, Hmiel SP, Landt M: Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997;82:847–850
- Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS).Kidney Int 1985;28:526–534.
- Jindal KH, Manuel A, Goldstein MB: Percent reduction in blood area concentration during hemodialysis. ASAIO Trans 1987;33:286–288.
- Grunfield C, Zhao C, Fuller J, Pollok A, Moser A, Friedman J, Feingold KR: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996;97:2152–2157.
- Stenvinkel P, Heimbürger O, Lönnqvist F: Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrol Dial Transplant 1997;12:1321–1325.
Article / Publication Details
Published online: September 04, 1998
Issue release date: September 1998
Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 4
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
